Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia

Candiolo, Torino 10060

0 studies enrolling now · 2 studies all time

What they study most

Adjuvant, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, Metastatic Melanoma, NSCLC, Stage IB-IIIA, Post-surgical, Uncommon EGFR Mutations

Studies at this site

• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma — Completed